Hep C's Needle-Free Revolution, FTC Merger Lifeline, Dog Cancer Monoclonals: January 2014 Biotech Shifts
Doctors and patients alike expected more interferon torture for Hep C. AbbVie shattered that with all-oral pills curing 96% of tough cases. Plus, FTC blocks price hikes, and dogs get human-like cancer drugs.
⚡ Key Takeaways
- AbbVie's interferon-free Hep C regimen achieves 92-96% cure rates in hard cases, set for quick regulatory push. 𝕏
- FTC settlement blocks anticompetitive Endo-Boca merger, safeguarding prices for kids' vitamins and other generics. 𝕏
- Aratana's AT-005 monoclonal pioneers targeted canine T-cell lymphoma therapy, de-risked by human parallels. 𝕏
Worth sharing?
Get the best Legal Tech stories of the week in your inbox — no noise, no spam.
Originally reported by IPWatchdog
Related Stories
IP & Copyright
Examiners' Secret Weapon: 25% of Patent Rejections Cite Invisible Prior Art
IP & Copyright
Federal Circuit's Nexus Ratchet Meets Its Match: Printed Matter's Symmetry Test
IP & Copyright
85% of PTAB Patents Face Parallel Court Battles: Congress's AIA Tilted the Scales
IP & Copyright